2022-09-14| Manufacturing

Government Agencies Spring into Action After Biomanufacturing Executive Order

by Max Heirich
Share To

On September 14, the U.S. Department of Health and Human Services (HHS) announced actions the department plans on taking in response to the Executive Order signed on September 12 by President Biden. These plans involve the investment of $40 million in biomanufacturing. In addition, the Department of Defense (DoD) The Executive Order launched a National Biotechnology and Biomanufacturing Initiative.

Related Article: Forge Biologics Raises $90 Million To Expand Gene Therapy CDMO

The National Biotechnology and Biomanufacturing Initiative

President Biden launched the National Biotechnology and Biomanufacturing Initiative (NBBI) via an Executive Order. The initiative’s purpose is to bolster the United States’ biomanufacturing in accordance with the values and principles of the country while simultaneously doing so in an ecologically sustainable manner. 

To fulfill the administration’s order, the HHS will invest $40 million to expand biomanufacturing for active pharmaceutical ingredients (APIs), antibiotics, and the key starting materials needed to produce essential medications and respond to pandemics. In addition, the HSS will support the development of Food and Drug Administration (FDA) research programs for advanced manufacturing technologies, as well as those in the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER)

The HHS will also leverage biotechnology and biomanufacturing to achieve medical breakthroughs, reduce the overall burden of disease, and improve health outcomes throughout the country. 

In addition, the DoD announced their planned $1 billion investment in bioindustrial domestic manufacturing infrastructure. The agency will dole the funds out over a period of five years in order to catalyze the establishment of a domestic bioindustrial manufacturing base that is accessible to U.S. innovators. They will also invest an additional $200 million in support of improving biosecurity and cybersecurity for these facilities.

On the DoD’s plan, the HHS said in a blog post, “This support will provide incentives that will enable private- and public-sector partners to expand manufacturing capacity for products important for defense supply chains, such as critical chemicals.”

The collaboration between these agencies will likely revolutionize the United States’ biomanufacturing industry in the coming years, creating thousands of new jobs and rejuvenating an economy battered by the COVID-19 Pandemic.

© All rights reserved. Collaborate with us: [email protected]
Related Post
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
Ginkgo Bioworks and Merck’s Collaboration Worth Up to $144 million
Will Biden’s Biomanufacturing Initiative Kill Korean Partnership?
Accelerated Bio and Pluristyx Generate Clinical-Grade Induced Pluripotent Stem Cells from Reprogrammed Human Trophoblast Stem Cells
Novo Nordisk and PT Bio Farma Agree to Enhance Insulin Production for Diabetes Patients in Indonesia
Alzheimer’s Drug LEQEMBI Approved for Treatment in Hong Kong
Foreseen Biotech Strikes $1.03B Deal with Ipsen for First-in-Class ADC
Synthetic Biology’s Innovator Dr. John Cumbers – Addressing Inefficiencies in Biopharma and Economic Sustainability
Delivering Affordable Biologic Medicines Worldwide: An Interview with Tanvex Chairman and CEO, Henry Chen
Roche Secures CE Mark for AI-Powered Glucose Monitoring Solution, Enhancing Diabetes Care with Predictive Insights
Scroll to Top